Rosetta Genomics Appoints Kevin Watson
News Feb 20, 2014
Rosetta Genomics Ltd. has announced the appointment of Kevin Watson to the newly established role of Director, Reimbursement-Managed Care.
Mr. Watson is a seasoned reimbursement specialist with nearly 25 years of experience in healthcare policy and reimbursement, managed care marketing, and new product development and commercialization.
"We are delighted to welcome Kevin to the Rosetta team to drive our reimbursement and managed care strategy and initiatives. Reimbursement is critical for commercial success and, as 2014 is a year of commercial execution for Rosetta, this is a timely and important hire for us," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "Kevin's experience devising strategic marketing, growth, and operational plans directed to the payer, integrated health system, hospital and distributor channels will be an invaluable asset for Rosetta as we execute our commercial plans for our current suite of cancer testing services and plan for the launch of future microRNA-based diagnostics."
Mr. Watson joins Rosetta Genomics from competing molecular diagnostics company, bioTheranostics, where for two years he was the Director of Reimbursement. Prior to this, Mr. Watson was the President of GlobalPayer, a payer relations and reimbursement consulting and outsourcing company serving providers and manufacturers in the medical device and diagnostic industry.
Mr. Watson was the Regional Marketing/Payer Relations Director at Becton Dickinson Diagnostics - TriPath Imaging for 6 years, where he was responsible for the development, execution and management of reimbursement outcomes with large payer organizations, Medicare and Medicaid.
Previous to that, Mr. Watson held positions as Executive Director, Business Development at LabCorp., and Network Product Development Leader, Executive Director with Quest Diagnostics, Inc. Mr. Watson started his career in payer management at Aetna Health Plans, where he spent four years as Administrator, National Vendor Contracting.
"This is an exciting time to be joining Rosetta to develop and manage the Company's payer relations strategy," said Kevin Watson. "Rosetta's cancer testing services provide critical and objective diagnostic data that may help physicians to select optimal treatment options and improve patient outcomes. I am looking forward to working with the Rosetta team as we build and expand the Company's microRNA diagnostic product offerings to bring truly personalized medicine to patients."
Non-Coding DNA Variants Increase Autism RiskNews
Whilst the contribution of gene variants to autism risk is well-established, the contribution of the 98% of the genome that does not code for gene sequences is still relatively unknown. Now, a new study has identified regulatory elements as potential genetic risk factors.READ MORE
Blood Test To Determine When It Is Safe To Return To Play After A Sports-related ConcussionNews
A high-sensitive blood test can aid concussed hockey players when it might be safe to return to play. In a study published by the journal Neurology, researchers at Sahlgrenska Academy have identified a superior blood-based biomarker for assessing subtle brain injury.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018